Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose SCO-792 Phase 1 PK and safety study in healthy adults
jRCT2080223770Phase 1
- Sponsor
- SCOHIA PHARMA, Inc.
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Sucunamostat (4 arms), sponsored by SCOHIA PHARMA, Inc. Primary endpoints: Safety and tolerability of multiple doses of SCO-792 and Pharmacokinetics of multiple doses of SCO-792.
02
Drugs
Sucunamostat
Beyond the preview
Go deeper on jRCT2080223770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223770.